TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10920309

Group type: EXPERIMENTAL
Intervention: 200 mg danazol 3 times daily for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprolide depot every 28 days for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 women without endometriosis)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-treatment (3 months after treatment)
Number of subjects: 20
Study: 8604441

Group type: EXPERIMENTAL
Intervention: Electrophysiologic Study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Holter Monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other Drugs
Number of subjects: 0
Study: 1575287

Group type: EXPERIMENTAL
Intervention: Praziquantel (20 mg/kg or 40 mg/kg body weight)
Number of subjects: 322
Study: 3907790

Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg . kg‐1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Thiopentone (4 mg . kg‐1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Thiopentone)
Number of subjects: 62
Study: 30213882

Group type: EXPERIMENTAL
Intervention: Pramlintide coadministered with regular human insulin (fixed ratio 9 μg/unit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo coadministered with regular human insulin
Number of subjects: 0
Study: 25670810

Group type: EXPERIMENTAL
Intervention: Train‐Colonoscopy‐Leaders (TCLs) programme (assessment, hands‐on training, post‐training feedback)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Feedback only (individual quality measures)
Number of subjects: 24
Study: 25023385

Group type: EXPERIMENTAL
Intervention: Functional hand splint only (n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Functional hand splint combined with task-specific training (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Task-specific training only (n=15)
Number of subjects: 30
Study: 22726710

Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 7
Study: 20042769

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2 g/d)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 108
Study: 18285347

Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinical pathway (12 visits over 6 weeks)
Number of subjects: 91
Study: 15809478

Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 5 days after clinical deterioration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 10 days after clinical deterioration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 30 days after clinical deterioration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 2 days after clinical deterioration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI SPECT at 30 days after clinical deterioration (second examination for group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of 99mTc‐MIBI indices among the 4 groups
Number of subjects: 32
Study: 14564683

Group type: EXPERIMENTAL
Intervention: l-thyroxine therapy (1.8 mug/kg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 10850524

Group type: EXPERIMENTAL
Intervention: gatifloxacin 400 mg/day orally
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg twice/day orally
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 8792382

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 100 micrograms once daily (od)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 100 micrograms twice daily (bd)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDPANS) 200 micrograms bd
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms od
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 1636712

Group type: EXPERIMENTAL
Intervention: Erythromycin (6 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 14
Study: 6533789

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C) 1 gram administered randomly to healthy young people for two months
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C) 1 gram administered to healthy older people for six to twelve months
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vitamin C) 1 gram per day administered throughout the year
Number of subjects: 2

Group type: COMPARATOR
Intervention: Seasonal observations on a mixed age group of healthy people (aged 38 +/- 12 years)
Number of subjects: 2
Study: 31209718

Group type: EXPERIMENTAL
Intervention: Clinical medication review (CMR)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study: 29114770

Group type: EXPERIMENTAL
Intervention: Infant-directed speech (IDS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Adult-directed speech (ADS)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Infant-directed speech (IDS) preference quotient
Number of subjects: 46
Study: 25841956

Group type: EXPERIMENTAL
Intervention: TF in rotary motion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TF Adaptive
Number of subjects: 30

Group type: COMPARATOR
Intervention: ProTaper Universal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TF
Number of subjects: 30
Study: 24260894

Group type: EXPERIMENTAL
Intervention: Dicarbamine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 2
Study: 21860562

Group type: EXPERIMENTAL
Intervention: Vitamin K + vitamin D + calcium supplement (15 mg of vitamin K2 three times daily, 400 IU of vitamin D once a day, and 315 mg of calcium twice daily)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vitamin K + vitamin D + calcium supplement
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (vitamin D + calcium supplement)
Number of subjects: 78
Study: 19339136

Group type: EXPERIMENTAL
Intervention: Low-fidelity condition
Number of subjects: 147

Group type: COMPARATOR
Intervention: High-fidelity condition
Number of subjects: 147
Study: 16352379

Group type: EXPERIMENTAL
Intervention: EMLA (local anaesthetic cream)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 14745753

Group type: EXPERIMENTAL
Intervention: Half-dose MR angiography using diluted contrast medium injected at a rate of 1 mL/second
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Half-dose MR angiography using diluted contrast medium injected at a rate of 0.5 mL/second
Number of subjects: 72

Group type: COMPARATOR
Intervention: Full-dose MR angiography using original concentration injected at a rate of 1 mL/second
Number of subjects: 72

Group type: COMPARATOR
Intervention: Full-dose MR angiography using original concentration injected at a rate of 0.5 mL/second
Number of subjects: 72
Study: 11694767

Group type: EXPERIMENTAL
Intervention: Platin-based chemotherapy including new drugs (vinorelbine, gemcitabine, paclitaxel, docetaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs in combination with platin-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-platin-based combinations
Number of subjects: 0
Study: 9778204

Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride (started at 25 mg before bed, titrated to 75 mg/d or maximal tolerated dose)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo (matched to nortriptyline)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride
Number of subjects: 214
Study: 8151049

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 3597656

Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partial mastectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study: 30318066

Group type: EXPERIMENTAL
Intervention: Volanesorsen sodium (antisense inhibitor of apolipoprotein C‐III)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fibrates
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fish oils
Number of subjects: 66

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 66
Study: 28133878

Group type: EXPERIMENTAL
Intervention: Acne RA-1,2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26075317

Group type: EXPERIMENTAL
Intervention: dTpa booster using the new syringe presentation (dTpa-new)
Number of subjects: 671

Group type: COMPARATOR
Intervention: dTpa booster using the previous syringe presentation (dTpa-previous)
Number of subjects: 671
Study: 23095336

Group type: EXPERIMENTAL
Intervention: Prolonged treadmill exercise
Number of subjects: 7
Study: 21587143

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (65 mL fermented milk drink containing 6.5×10^9 CFU daily)
Number of subjects: 40
Study: 17717533

Group type: EXPERIMENTAL
Intervention: Protein hydrolysate (0.4 g kg(‐1) bw casein hydrolysate, PRO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Protein hydrolysate (PRO)
Number of subjects: 13
Study: 16837886

Group type: EXPERIMENTAL
Intervention: Oral E(2)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: E(2) with NETA
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Transdermal E(2)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 14738630

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 2530

Group type: COMPARATOR
Intervention: Control group (non-converted cases)
Number of subjects: 2530
Study: 10872641

Group type: EXPERIMENTAL
Intervention: Ethanol infusion (100 mg/dL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% dextrose in water infusion
Number of subjects: 10
Study: 9119421

Group type: EXPERIMENTAL
Intervention: Age-related changes in the brain (senile plaques and neurofibrillary tangles)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease cases studied
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Amyloid immunostaining
Number of subjects: 52
Study: 8468875

Group type: EXPERIMENTAL
Intervention: Blood glucose monitor (BGM) intervention, finger stick test in triage area.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group, no finger stick test.
Number of subjects: 68
Study: 2834482

Group type: EXPERIMENTAL
Intervention: CY 222 at 150 U/kg + 1,000 U/h
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CY 222 at 300 U/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CY 222 at 200 U/kg and 250 U/kg (single-dose injection)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard heparin (SH)
Number of subjects: 21
Study: 29273688

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients with FMD
Number of subjects: 21
Study: 27671673

Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) implant
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 1328
Study: 24983797

Group type: EXPERIMENTAL
Intervention: Consistent exposure (CE)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Varied exposure (VE)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Neutral control (NC)
Number of subjects: 57
Study: 22296168

Group type: EXPERIMENTAL
Intervention: beer/no-go condition
Number of subjects: 57

Group type: COMPARATOR
Intervention: beer/go condition
Number of subjects: 57
Study: 21095492

Group type: EXPERIMENTAL
Intervention: Test formulation of fluoxetine hydrochloride 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of fluoxetine hydrochloride 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 18240991

Group type: EXPERIMENTAL
Intervention: TalkToYourDoc (TTYD) website module
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288
Study: 16492585

Group type: EXPERIMENTAL
Intervention: Erythromycin 400 mg orally every 6 hours for 10 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12580656

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg every 8 hours for 48 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10933096

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 39
Study: 9354005

Group type: EXPERIMENTAL
Intervention: Elevated maternal serum beta-hCG levels
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normotensive mothers
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Proteinuric pregnancy induced hypertension
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Severe pregnancy hypertension
Number of subjects: 105
Study: 8473263

Group type: EXPERIMENTAL
Intervention: Whole-word error correction (teacher stated the complete word and the student repeated it)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Phonetic-prompt error correction (teacher provided phonetic prompts)
Number of subjects: 5
Study: 3899020

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma 10 ml/kg on admission and at 24 hours of age
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 73
Study: 31557603

Group type: EXPERIMENTAL
Intervention: Fresh air ventilation system with high efficiency particulate air filter (FAVS-HEPA)
Number of subjects: 43
Study: 28719366

Group type: EXPERIMENTAL
Intervention: Web-based anger management program for 8 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study: 25804970

Group type: EXPERIMENTAL
Intervention: Shorter stride length (±25% of desired stride length)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Longer stride length (±25% of desired stride length)
Number of subjects: 19
Study: 22836600

Group type: EXPERIMENTAL
Intervention: Single training workload (3 series of 6 throws with a 3‐kg medicine ball)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Double training workload (6 series of 6 throws with a 3‐kg medicine ball)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Training with 3-kg medicine balls
Number of subjects: 40
Study: 21818029

Group type: EXPERIMENTAL
Intervention: Brief in‐hospital psychoeducational violence intervention (BVI) alone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BVI + Community Case Management Services (CCMS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (BVI alone)
Number of subjects: 75
Study: 19702704

Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Acri.Smart 36A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Spherical IOL (Rayner Superflex 620H)
Number of subjects: 31
Study: 16415410

Group type: EXPERIMENTAL
Intervention: Toremifen (30 mg daily for 3 menstrual cycles)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 15322598

Group type: EXPERIMENTAL
Intervention: ACEIs alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ACEI and digoxin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard therapy excluding ACEIs
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ACEI regimens
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combination of ACEI and digoxin
Number of subjects: 78
Study: 11208939

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High Oleic Sunflower Oil (HOSO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 8
Study: 9290119

Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/day) for three months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/day)
Number of subjects: 37
Study: 8359618

Group type: EXPERIMENTAL
Intervention: 5 MU of interferon tiw
Number of subjects: 65

Group type: COMPARATOR
Intervention: 3 MU of interferon tiw
Number of subjects: 65
Study: 3712182

Group type: EXPERIMENTAL
Intervention: Nonsmokers' perceptions of reasons for smoking (Reasons for Smoking Scale)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Criterion group of smokers (N = 81) who completed the Reasons scale
Number of subjects: 175
Study: 31603268

Group type: EXPERIMENTAL
Intervention: Intravenous dopamine (2 µg kg‐1 min‐1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous saline and D2‐receptor antagonist (20 mg oral metoclopramide)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous saline and placebo pill
Number of subjects: 14
Study: 28748625

Group type: EXPERIMENTAL
Intervention: Full counseling (face-to-face cardiovascular risk assessment and personalized counseling on nutrition, physical activity, and smoking cessation in the ED, plus two telephone follow-up sessions)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Minimal counseling (brief instruction [<5 minutes] on benefits of modifying cardiovascular risk factors)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both treatment arms combined
Number of subjects: 140
Study: 25061028

Group type: EXPERIMENTAL
Intervention: Electrical muscle elongation (EME) session of 4 KHz interferential current, bipolar technique and AMF = 100 Hz, n = 40
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT), n = 40
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention, n = 40)
Number of subjects: 120
Study: 23124781

Group type: EXPERIMENTAL
Intervention: Intensified blood pressure control
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional blood pressure control
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ACE inhibition with improved BP control
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 84
Study: 22122912

Group type: EXPERIMENTAL
Intervention: Carer Assisted Adherence Therapy (CAAT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 80
Study: 19369114

Group type: EXPERIMENTAL
Intervention: PDA-based survey
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paper-based survey
Number of subjects: 120
Study: 16505207

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB; candesartan 8 mg/day, n=11 or valsartan 80 mg/day, n=22)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Trichlormethiazide (2 mg/day)
Number of subjects: 66
Study: 14722001

Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting technique
Number of subjects: 112

Group type: COMPARATOR
Intervention: Traditional harvesting technique
Number of subjects: 112
Study: 11763912

Group type: EXPERIMENTAL
Intervention: Essential oil-containing dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 8875516

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (group AA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (group ALAGLN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (glucose alone)
Number of subjects: 30
Study: 1863724

Group type: EXPERIMENTAL
Intervention: DDAVP (desmopressin acetate) 0.3 microgram/kg infused intravenously over 5 seconds (group 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DDAVP (desmopressin acetate) 0.3 microgram/kg administered over 5 minutes (group 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Phenylephrine infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DDAVP (desmopressin acetate)
Number of subjects: 16
Study: 6395275

Group type: EXPERIMENTAL
Intervention: Cefonicid (1,000 mg once daily, with some patients receiving 500 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefamandole (1,000 mg every 6 hours)
Number of subjects: 100
Study: 30802720

Group type: EXPERIMENTAL
Intervention: 900 mg of spearmint extract (PSE)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 142
Study: 29996895

Group type: EXPERIMENTAL
Intervention: New Start intervention, delivered approximately 6 months post-stroke by trained staff (facilitators)
Number of subjects: 0
Study: 25808690

Group type: EXPERIMENTAL
Intervention: Minimized collar (MC) implant at crestal bone level
Number of subjects: 33

Group type: COMPARATOR
Intervention: Long collar (LC) implant 2.5 mm supracrestal
Number of subjects: 33
Study: 25350960

Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF)
Number of subjects: 708

Group type: COMPARATOR
Intervention: atazanavir+ritonavir+emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF)
Number of subjects: 708
Study: 22503786

Group type: EXPERIMENTAL
Intervention: Nebulised frusemide (40 mg, 4 ml)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline (4 ml)
Number of subjects: 32
Study: 19876062

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg before sleep)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16896917

Group type: EXPERIMENTAL
Intervention: Ocular hypertension patients
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 15623995

Group type: EXPERIMENTAL
Intervention: Ball-spring attachment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bar-clip attachment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both attachment mechanisms
Number of subjects: 100
Study: 12118494

Group type: EXPERIMENTAL
Intervention: 0.5 mg droperidol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5.0 mg metoclopramide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (intravenous normal saline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups (droperidol, metoclopramide, placebo)
Number of subjects: 150